Renovaro BioSciences

Renovaro BioSciences, founded in 2013 and based in Los Angeles, is developing an AI-driven biology platform under the Lunai Bioworks banner to transform drug discovery. The company integrates genomic, proteomic, and phenotypic data with high-throughput in vivo modeling to uncover disease mechanisms and therapeutic candidates with higher precision. It is advancing internal programs in oncology and neurology while also pursuing strategic partnerships with pharmaceutical companies. Renovaro is a public company, positioning itself at the intersection of AI and biologics to address complex diseases.

Integrated AI/ML engine (Augusta) for multi-omic data analysis, a translational prioritization system (Phenograph), and high-throughput in vivo modeling in zebrafish with machine vision for real-time phenotypic validation.

Renovaro competes in the crowded AI-for-drug-discovery space against pure-play AI companies (e.g., Recursion, Exscientia) and large pharma internal efforts. Its differentiation lies in the tight integration of its AI with high-throughput, dynamic in vivo validation, a combination less common than purely computational or cell-based approaches.